SAR003
Gastrointestinal Stromal Tumor (GIST)
Key Facts
About Sartar Therapeutics
Sartar Therapeutics is a private, preclinical-stage biotech developing SAR003, a first-in-class molecular glue therapy targeting cancers with high PDE3A expression. The company has secured Orphan Drug Designations from both the FDA and EMA for GIST, demonstrating regulatory recognition of its approach for an unmet medical need. With strong IP protection and a seasoned team, Sartar is transitioning from preclinical development into clinical trial preparations and drug manufacturing. The company is positioned to address a significant niche in oncology with a novel mechanism of action.
View full company profileAbout Sartar Therapeutics
Sartar Therapeutics is a private, preclinical-stage biotech developing SAR003, a first-in-class molecular glue therapy targeting cancers with high PDE3A expression. The company has secured Orphan Drug Designations from both the FDA and EMA for GIST, demonstrating regulatory recognition of its approach for an unmet medical need. With strong IP protection and a seasoned team, Sartar is transitioning from preclinical development into clinical trial preparations and drug manufacturing. The company is positioned to address a significant niche in oncology with a novel mechanism of action.
View full company profileTherapeutic Areas
Other Gastrointestinal Stromal Tumor (GIST) Drugs
| Drug | Company | Phase |
|---|---|---|
| Famitinib (SHR-1020) | Jiangsu Hengrui Medicine | Approved |
| Pasritamig | Zymeworks | Phase 2/3 |